A next-generation CGM platform built on a compact, low-cost, silicon-first architecture — designed from the ground up for long-term implantable medical devices.
Introducing an RF-free optical-frequency communication architecture enabling a new class of semiconductor-native implantable systems.
Continuous glucose monitoring is entering a structural transition. While wearables dominate today, the long-term future of CGM lies in fully implantable systems that are reliable, unobtrusive, and economically scalable.
Our vision is to enable this transition by rethinking CGM not as an assembled device, but as an integrated semiconductor platform.
Current implantable CGM systems remain constrained by RF-based communication subsystems. These electronics — not the sensors — impose fundamental system limits.
Our platform introduces a proprietary optical-frequency signaling architecture that removes the entire RF communication subsystem from implantable biosensors.
This is not a communication improvement — it is a system architecture shift.
The core concept is protected by an international PCT patent and designed to scale across future implantable biosensing applications.
Developer of the Eversense® long-term implantable CGM system.
www.senseonics.com
Developer of the Sencell implantable nanobiosensor platform.
www.lifecare.no
While these leaders demonstrate clinical progress, existing systems remain rooted in RF-centric architectures. Our platform proposes a fundamentally different semiconductor-native, RF-free approach.
We are seeking strategic partners and investors who understand the long-term value of architectural innovation in implantable medical devices.
Collaboration opportunities include joint development, system integration, and future commercialization.
Contact: Thomas
ygcho@anasenics.com